The N-MOmentum study - a randomised, placebo-controlled, double-blind trial of Inebilizumab for neuromyelitis optica spectrum disorder: randomised controlled period and open-label extension results

被引：0

作者：

Cree, B. ^{[1
]}

Bennett, J. ^{[2
]}

Kim, H. J. ^{[3
]}

Weinshenker, B. ^{[4
]}

Pittock, S. ^{[4
]}

Wingerchuk, D. ^{[5
]}

Fujihara, K. ^{[6
]}

Paul, F. ^{[7
,8
,9
]}

Cutter, G. ^{[10
]}

Marignier, R. ^{[11
]}

Green, A. ^{[1
]}

Aktas, O. ^{[12
]}

Hartung, H. -P. ^{[12
]}

Lublin, F. ^{[13
]}

Mealy, M. ^{[14
]}

Drappa, J. ^{[14
]}

Barron, G. ^{[15
]}

Madani, S. ^{[14
]}

Shi, D. ^{[14
]}

Cimbora, D. ^{[14
]}

Rees, W. ^{[14
]}

Ratchford, J. ^{[14
]}

Katz, E. ^{[14
]}

机构：

[1] Univ Calif San Francisco, Weill Inst Neurosci, Neurol, San Francisco, CA 94143 USA

[2] Univ Colorado, Sch Med, Neurol & Ophthalmol, Denver, CO USA

[3] Res Inst & Hosp Natl Canc Ctr, Goyang, South Korea

[4] Mayo Clin, Rochester, MN USA

[5] Mayo Clin, Scottsdale, AZ USA

[6] Fukushima Med Univ, Sch Med, Fukushima, Japan

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Humboldt Univ, Freie Univ Berlin, Berlin, Germany

[9] Berlin Inst Hlth, Berlin, Germany

[10] Univ Alabama Birmingham, Birmingham, AL USA

[11] Hosp Civils Lyon, Lyon, France

[12] Heinrich Heine Univ, Dusseldorf, Germany

[13] Mt Sinai Hosp, New York, NY 10029 USA

[14] Viela Bio, Gaithersburg, MD USA

[15] Astrazeneca, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

139

引用

页码：42 / 44

页数：3

共 50 条

[21] Treatment of cyclical mastalgia: Results of a randomised, placebo-controlled, double-blind study
Wuttke, W
Splitt, G
Gorkow, C
Sieder, C
GEBURTSHILFE UND FRAUENHEILKUNDE, 1997, 57 (10) : 569 - 574
[22] Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia
Pizzolato, G
Cagnin, G
Mancia, D
Caffarra, P
Avanzi, S
Copelli, S
Ciappina, C
Lo Presti, F
Spilimbergo, PG
D'Antonio, E
Di Costanzo, E
Matrango, M
Pastres, P
Urbani, PP
Signorino, M
Simoncelli, M
Provinciali, L
Regnicolo, L
Albano, C
Roccatagliata, G
Rubino, V
Cultrera, S
Fracassi, M
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1997, 47 (11A): : 1329 - 1331
[23] A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
Shiina, Akihiro
Shirayama, Yukihiko
Niitsu, Tomihisa
Hashimoto, Tasuku
Yoshida, Taisuke
Hasegawa, Tadashi
Haraguchi, Tadashi
Kanahara, Nobuhisa
Shiraishi, Tetsuya
Fujisaki, Mihisa
Fukami, Goro
Nakazato, Michiko
Iyo, Masaomi
Hashimoto, Kenji
ANNALS OF GENERAL PSYCHIATRY, 2010, 9
[24] A randomised, double-blind, placebo-controlled trial of a Bach Flower Remedy
Armstrong, NC
Ernst, E
PERFUSION, 1999, 12 (11): : 440 - 446
[25] A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
Akihiro Shiina
Yukihiko Shirayama
Tomihisa Niitsu
Tasuku Hashimoto
Taisuke Yoshida
Tadashi Hasegawa
Tadashi Haraguchi
Nobuhisa Kanahara
Tetsuya Shiraishi
Mihisa Fujisaki
Goro Fukami
Michiko Nakazato
Masaomi Iyo
Kenji Hashimoto
Annals of General Psychiatry, 9
[26] Muscle strength and tibolone: a randomised, double-blind, placebo-controlled trial
Meeuwsen, IBAE
Samson, MM
Duursma, SA
Verhaar, HJJ
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2002, 109 (01) : 77 - 84
[27] Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial
Gauvreau, Gail M.
Sehmi, Roma
Fitzgerald, J. Mark
Leigh, Richard
Cockcroft, Donald W.
Davis, Beth E.
Mayers, Irvin
Boulet, Louis-Philippe
Al-Sajee, Dhuha
Salter, Brittany M.
Cusack, Ruth P.
Ho, Terence
Whetstone, Christiane E.
Alsaji, Nadia
Satia, Imran
Killian, Kieran J.
Mitchell, Patrick D.
Magee, Iain P.
Bergeron, Celine
Bhutani, Mohit
Werkstrom, Viktoria
Durzynski, Tomasz
Shoemaker, Kathryn
Katial, Rohit K.
Jison, Maria
Newbold, Paul
Mccrae, Christopher
O'byrne, Paul M.
EUROPEAN RESPIRATORY JOURNAL, 2024, 64 (03)
[28] Elevated Serum Glial Fibrillary Acidic Protein (sGFAP) is Associated With Increased Risk of Neuromyelitis Optica Spectrum Disorder Attacks in the N-Momentum Randomized, Masked, Placebo-Controlled Clinical Trial of Inebilizumab
Aktas, O.
Smith, M. A.
Rees, W.
Fujihara, K.
Paul, F.
Hartung, H-P
Marignier, R.
Bennett, J. L.
Kim, H. J.
Weinshenker, B. G.
Pittock, S. J.
Wingerchuk, D.
Cutter, G.
Green, A.
Mealy, M. A.
Drappa, J.
Barron, G.
Madani, S.
Wang, L.
She, D.
Cimbora, D.
Ratchford, J. N.
Katz, E.
Cree, B. A. C.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP42 - NP43
[29] Growth hormone deficiency and replacement therapy in Japan: Results of placebo-controlled double-blind study and open-label extension study
Shimatsu, A.
Tai, S.
Kato, Y.
Kohno, H.
Tanaka, T.
Teramoto, A.
Chihara, K.
DECADE OF HYPOCCS: THE CHANGING FACE OF PITUITARY DISEASE, 2008, 10 : 171 - +
[30] Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Kapoor, Raja
Ho, Pei-Ran
Campbell, Nolan
Chang, Ih
Deykin, Aaron
Forrestal, Fiona
Lucas, Nisha
Yu, Bei
Arnold, Douglas L.
Freedman, Mark
Goldman, Myia D.
Hartung, Hans-Peter
Kubala Havrdova, Eva
Jeffery, Douglas
Miller, Aaron
Sellebjerg, Finn
Cadavid, Diego
Mikol, Dan
Steiner, Deborah
LANCET NEUROLOGY, 2018, 17 (05): : 405 - 415

← 1 2 3 4 5 →